Objectif
We propose to develop new strategies to mobilize skeletal muscle tissue-associated stem cells as a tool for efficient tissue repair. This will be combined with exploring novel approaches that limit tissue damage, and will focus on agents that modify muscle and muscle vasculature progenitor cells. These molecules include nitric oxide associated with non-steroidal anti-inflammatory drugs, HMGB1, Cripto, NAC, and present and improved deacetylase inhibitors. Three clinical trials will be run in tandem with efforts to dissect the underlying mechanisms of action. Importantly, we have already initiated a monocentric clinical trial that focuses on the efficacy of NO-donors plus NSAIDs in muscle pathologies. Our efforts will be complemented by novel biodelivery systems for effective targeting. Our efforts will be complemented by novel biodelivery systems for effective targeting. The most promising drugs, used alone or in combination, will be first validated in small and large animal models. Our project brings together leading investigators to examine how vascular and muscle progenitors participate in postnatal growth and muscle tissue repair. A key issue that this project addresses is the tissue environment in which endogenous stem cells are activated. We propose that muscle degeneration and fibrosis provokes altered vascularization and immune responses, which eventually affect negatively stem cell functions. Molecules that can be used to therapeutically target these key cells, and their communication with neighboring vascular, inflammatory and fibrotic cell types, will lead to more effective approaches to muscle regenerative medicine and to novel cures for degenerative diseases, including atherosclerosis, vascular damage in diabetes and in peripheral ischemic vascular disease.
Champ scientifique
- medical and health sciencesclinical medicineangiologyvascular diseases
- medical and health sciencesclinical medicinecardiologycardiovascular diseasesarteriosclerosis
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
Appel à propositions
FP7-HEALTH-2009-single-stage
Voir d’autres projets de cet appel
Régime de financement
CP-IP - Large-scale integrating projectCoordinateur
75252 PARIS
France
Voir sur la carte
Participants (21)
00185 Roma
Voir sur la carte
22037 Ponte Lambro
Voir sur la carte
1015 Lausanne
Voir sur la carte
69117 Heidelberg
Voir sur la carte
4056 Basel
Voir sur la carte
20132 MILANO
Voir sur la carte
20139 Milano
Voir sur la carte
Participation terminée
00185 Roma
Voir sur la carte
08002 Barcelona
Voir sur la carte
60323 Frankfurt Am Main
Voir sur la carte
20133 Milano
Voir sur la carte
Participation terminée
28760 MADRID
Voir sur la carte
Participation terminée
BA2 9ER BATH
Voir sur la carte
Participation terminée
EC4A 3TW London
Voir sur la carte
Participation terminée
L3 5UX Liverpool
Voir sur la carte
20126 Milano
Voir sur la carte
4410 LIESTAL
Voir sur la carte
75654 Paris
Voir sur la carte
WC2R 2LS London
Voir sur la carte
00179 Roma
Voir sur la carte
20132 Milano
Voir sur la carte